Larry's Story: The Power of Patient Advocacy
For Larry, patient advocacy is an important part of his cancer journey. Learn more about Larry and his role with GO2 for Lung Cancer.
Search
Oncology & Cancer Immunology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
Facing Lung Cancer: Keith’s Story
Facing Lung Cancer: Keith’s Story
Bringing focus to unmet needs in biliary tract and pancreatic cancer with the Brightline-2 Trial
Brightline-2 clinical trial is studying our investigational MDM2-p53 antagonist for people with advanced cancer in the biliary tract or pancreatic cancer.
AbeXXa Biologics – Re-Imagining Cancer Immunotherapy for the Many
AbeXXa Biologics – Re-Imagining Cancer Immunotherapy for the Many
Protein Degraders: Changing the Game in Cancer Drug Discovery
Protein Degraders: Changing the Game in Cancer Drug Discovery
Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies
Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies
Positive results reported in HER2 mutated lung cancer
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
Final analysis of the observational GioTag study: Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small cell lung cancer
Final analysis of the observational GioTag study: Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small cell lung cancer
Expert insights: top online lung cancer questions answered
As part of Big Little Things, we teamed up with top patient representatives from around the world to answer the most searched questions about lung cancer.
Overcoming stigma and advancing lung cancer advocacy
As part of Big Little Things, we teamed up with top patient representatives from around the world to answer the most searched questions about lung cancer.
Exploring T-cells in cancer
Lamine Mbow, our Global Head of Cancer Immunology and Immune Modulation, shares our approach to immuno-oncology, highlighting our investigational T-cell engagers platform and how we are driving innovation to potentially deliver meaningful advances to peop
Oncology & Cancer Immunology
Oncology & Cancer Immunology
Boehringer Ingelheim Acquires AMAL Therapeutics
Boehringer Ingelheim Acquires AMAL Therapeutics
Are combination therapies the answer to battling KRAS cancers?
Dr Ulrich Dünzinger and Kristie Fernamberg talk about their work with the SOS1 KRAS inhibitor to block tumour-triggering signal
Boehringer Ingelheim and Vanderbilt University join forces to develop new Ras inhibitors for cancer treatment
Boehringer Ingelheim and Vanderbilt University join forces
BI initiates Study of Sequencing in EGFR Lung Cancer | BI US
Boehringer Ingelheim has initiated a real-world study to assess the impact of sequential therapy in patients with EGFR mutation-positive advanced NSCLC.
Boehringer Ingelheim collaborates with Circle Pharma
Boehringer Ingelheim collaborates with Circle Pharma to develop a first-in-class cyclin RxL inhibitor that can halt the growth of cancer cells
Confronting health disparities in clinical trials
As a research-driven pharmaceutical company, one of our priorities is to ensure there’s more representation from underserved communities, particularly for clinical cancer trials.
Our Partners: ViraTherapeutics
Our Partners: ViraTherapeutics
Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic
Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic
Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing
Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing
Our goal of transforming DLL3-positive carcinomas
Our progress in developing a potential immunotherapy for DLL3-positive carcinomas.